Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Evaluating Chitosan Nerve Conduits That Bridge Sciatic Nerve Defects Visualized Using Ultrasound Imaging

By BiotechDaily International staff writers
Posted on 27 Aug 2014
Image: Ultrasound image of the morphology of a chitosan nerve conduit in a rat model of sciatic nerve defects at three weeks after modeling (Photo courtesy of Neural Regeneration Research journal).
Image: Ultrasound image of the morphology of a chitosan nerve conduit in a rat model of sciatic nerve defects at three weeks after modeling (Photo courtesy of Neural Regeneration Research journal).
ADVERTISEMENT
SARTORIUS AG
The first use of ultrasound has been used by Chinese researchers to noninvasively observe the changes in chitosan nerve conduits implanted in lab rats over time.

The investigators reported that newer, simpler, and more effective ways are needed to better assess the outcomes of repair using nerve conduits in vivo. The new technology distinctly revealed whether there are unsatisfactory complications after implantation, such as fracture, collapse, bleeding, or unusual swelling of the nerve conduits; and reflected the degradation mode of the nerve conduit in vivo over time.

Ultrasound is a common noninvasive clinical detection modality that has been used in many fields. However, ultrasound has seldom been used to observe implanted nerve conduits in vivo.

Dr. Hongkui Wang and coworkers from Affiliated Hospital of Nantong University (Nantong, Jiangsu Province, China) reported on their findings July 15, 2014, in the journal Neural Regeneration Research. Ultrasound, as a noninvasive imaging modality, they noted, can be used as a supplementary observation technique during standard animal research on peripheral nerve tissue engineering.

Related Links:

Affiliated Hospital of Nantong University



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.